Alkeon Capital Management Reduces $76M in Madrigal Pharmaceuticals, Inc. ($MDGL)
Key Points
- Alkeon Capital Management changed its Madrigal Pharmaceuticals, Inc. ($MDGL) stake by 66.7% last quarter, cutting to 80,000 shares worth $37.94 million.
- Wall Street's consensus rating on $MDGL is Strong Buy and an average price target of $678.71.
- $MDGL last traded around $474.28.
Alkeon Capital Management reduced its position in Madrigal Pharmaceuticals, Inc. ($MDGL) by 66.7% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 80,000 shares of Madrigal Pharmaceuticals, Inc. after selling 160,000 shares during the quarter. Alkeon Capital Management's holdings in Madrigal Pharmaceuticals, Inc. were worth $37.94 million as of its most recent filing.
Madrigal Pharmaceuticals, Inc. ($MDGL) Stock
Madrigal Pharmaceuticals, Inc. Earnings
Analysts Set New Price Targets
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.